Immunic Market Capitalization from 2010 to 2025
| IMUX Stock | USD 0.94 0.01 0.99% |
Check Immunic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 94.9 K, Interest Expense of 730.2 K or Other Operating Expenses of 119.8 M, as well as many indicators such as Price To Sales Ratio of 17.3 K, Dividend Yield of 0.0064 or PTB Ratio of 1.46. Immunic financial statements analysis is a perfect complement when working with Immunic Valuation or Volatility modules.
Immunic | Market Capitalization |
Latest Immunic's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Immunic over the last few years. It is Immunic's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 85.85 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Immunic Market Capitalization Regression Statistics
| Arithmetic Mean | 250,856,237 | |
| Geometric Mean | 104,773,990 | |
| Coefficient Of Variation | 101.12 | |
| Mean Deviation | 219,396,043 | |
| Median | 226,357,095 | |
| Standard Deviation | 253,677,392 | |
| Sample Variance | 64352.2T | |
| Range | 586.2M | |
| R-Value | (0.80) | |
| Mean Square Error | 25219.8T | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | (42,433,540) | |
| Total Sum of Squares | 965283.3T |
Immunic Market Capitalization History
About Immunic Financial Statements
Immunic investors use historical fundamental indicators, such as Immunic's Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunic. Please read more on our technical analysis and fundamental analysis pages.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.